Répertoire du corps professoral
Francesca Cicchetti
Professeure titulaire
(418) 525-4444, poste 48853
francesca.cicchetti@fmed.ulaval.ca
Pavillon Ferdinand-Vandry
1050, avenue de la Médecine
Local 4873
Redefining PD pathophysiology mechanisms in the context of heterogeneous substantia nigra neuron subtypes
Programme: ASAP Collaborative Research Network
Organisme(s) subventionnaire(s): Michael J. Fox Foundation for Parkinson's Research
Type de financement: Subvention
Établissement tête: Northwestern University
Du 1 novembre 2024
au 31 octobre 2026
Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2020
au 31 mars 2025
Financements des 2 dernières années
Les effets de la cystéamine chez les patients souffrant de la maladie de Huntington : Analyse des données cliniques
Programme: Développement de la recherche (RFI)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 janvier 2023
au 31 décembre 2023
Premier biomarqueur sanguin de la maladie de Parkinson : de la validation à la commercialisation
Programme: Projets de maturation technologique PSO – volet 2d
Organisme(s) subventionnaire(s): Fondation du CHU de Québec, Synucure Thérapeutique inc., Ministère de l'Économie et de l'Innovation
Type de financement: Subvention
Établissement tête: Université Laval
Du 14 septembre 2022
au 13 septembre 2024
Crosstalk at the blood-brain barrier: new insights into Parkinson's disease
Organisme(s) subventionnaire(s): National Parkinson Foundation
Type de financement: Subvention
Établissement tête: Université Laval
Du 30 juin 2022
au 31 juillet 2023
Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 20 décembre 2021
au 19 décembre 2024
Redefining PD pathophysiology mechanisms in the context of teterogeneous substantia nigra neuron subtypes
Programme: Target Advancement Program
Organisme(s) subventionnaire(s): Northwestern University
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 septembre 2021
au 31 octobre 2024
Targeting the neurovascular unit to prevent disease dissemination and progression
Programme: Target Advancement Program
Organisme(s) subventionnaire(s): Michael J. Fox Foundation for Parkinson's Research
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 janvier 2021
au 31 mars 2023
Interrogating induced neuronal cells from Huntington’s disease patients to better understand cognitive impairments
Organisme(s) subventionnaire(s): Huntington's Disease Society of America
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 novembre 2019
au 30 juin 2023
Untangling tau contribution to cognitive impairments in Huntington’s disease.
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2019
au 31 mars 2024
Encadrements terminés dans les 5 dernières années
Publications des 5 dernières années
Healthy blood, healthy brain: a window into understanding and treating neurodegenerative diseases Journal of Neurology, 2024/06. Thyago R. Cardim-Pires, Aurélie de Rus Jacquet, Francesca Cicchetti. DOI 10.1007/s00415-024-12337-w
Tau: a biomarker of Huntington’s disease Molecular Psychiatry, 2023/10. Eva Lepinay, Francesca Cicchetti. DOI 10.1038/s41380-023-02230-9
Passive immunization against phosphorylated tau improves features of Huntington's disease pathology Molecular Therapy, 2022/04. Melanie Alpaugh, Maria Masnata, Aurelie de Rus Jacquet, Eva Lepinay, Hélèna L. Denis, Martine Saint-Pierre, Peter Davies, Emmanuel Planel, Francesca Cicchetti. DOI 10.1016/j.ymthe.2022.01.020
Prompting endogenous repair of brain injury: science fiction or reality? Molecular Neurodegeneration, 2022. de Rus Jacquet, A., Cicchetti, F.. DOI 10.1186/s13024-022-00539-7
A light-inducible protein clustering system for in vivo analysis of α-synuclein aggregation in ParkinsonAU disease: PleasenotethatParkinsonsdiseasehasbeen PLoS Biology, 2022. Bérard, M., Sheta, R., Malvaut, S., Rodriguez-Aller, R., Teixeira, M., Idi, W., Turmel, R., Alpaugh, M., Dubois, M., Dahmene, M., Salesse, C., Lamontagne-Proulx, J., St-Pierre, M.-K., Tavassoly, O., Luo, W., Cid-Pellitero, E.D., Qazi, R., Jeong, J.-W., Durcan, T.M., Vallières, L., Tremblay, M.-E., Soulet, D., Lévesque, M., Cicchetti, F., Fon, E.A., Saghatelyan, A., Oueslati, A.. DOI 10.1371/journal.pbio.3001578
Sox6 expression distinguishes dorsally and ventrally biased dopamine neurons in the substantia nigra with distinctive properties and embryonic origins. Cell reports, 2021/11/01. DOI 10.1016/j.celrep.2021.109975
Prion-like properties of the mutant huntingtin protein in living organisms: the evidence and the relevance. Molecular psychiatry, 2021/10/28. DOI 10.1038/s41380-021-01350-4
Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience. Parkinsonism & related disorders, 2021/09/01. DOI 10.1016/j.parkreldis.2021.08.018
Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders Molecular Psychiatry, 2021/07. Aurélie de Rus Jacquet, Hélèna L. Denis, Francesca Cicchetti, Melanie Alpaugh. DOI 10.1038/s41380-020-00999-7
Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders. Molecular psychiatry, 2021/07/01. DOI 10.1038/s41380-021-01055-8
Huntington's disease: lessons from prion disorders. Journal of neurology, 2021/02/24. DOI 10.1007/s00415-021-10418-8
Correction: Shedding a new light on Huntington’s disease: how blood can both propagate and ameliorate disease pathology (Molecular Psychiatry, (2021), 26, 9, (5441-5463), 10.1038/s41380-020-0787-4) Molecular Psychiatry, 2021. Rieux, M., Alpaugh, M., Sciacca, G., Saint-Pierre, M., Masnata, M., Denis, H.L., Lévesque, S.A., Herrmann, F., Bazenet, C., Garneau, A.P., Isenring, P., Truant, R., Oueslati, A., Gould, P.V., Ast, A., Wanker, E.E., Lacroix, S., Cicchetti, F.. DOI 10.1038/s41380-020-0850-1
Targeting Tau to Treat Clinical Features of Huntington's Disease. Frontiers in neurology, 2020/11/19. DOI 10.3389/fneur.2020.580732
Neuronal interleukin-1 receptors mediate pain in chronic inflammatory diseases. The Journal of experimental medicine, 2020/09/01. DOI 10.1084/jem.20191430
Beneficial effects of cysteamine in Thy1-α-Syn mice and induced pluripotent stem cells with a SNCA gene triplication. Neurobiology of disease, 2020/08/13. DOI 10.1016/j.nbd.2020.105042
Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology. Molecular psychiatry, 2020/06/08. DOI 10.1038/s41380-020-0787-4
Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates. Neurobiology of disease, 2020/05/18. DOI 10.1016/j.nbd.2020.104951
Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease. Neurobiology of disease, 2020/05/12. DOI 10.1016/j.nbd.2020.104943
Evidence for the spread of human-derived mutant huntingtin protein in mice and non-human primates. Neurobiology of disease, 2020/05/11. DOI 10.1016/j.nbd.2020.104941
Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology. Journal of neuroinflammation, 2020/04/02. DOI 10.1186/s12974-020-01782-9
The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. Journal of Parkinson's disease, 2020/01/01. DOI 10.3233/jpd-191775
Les informations contenues dans cette page sont extraites de différents systèmes experts de l’Université Laval. Si vous constatez une erreur ou avez des questions quant aux données affichées, communiquez avec nous en écrivant à l’adresse repertoire-corps-professoral@ulaval.ca. Nous nous assurerons de rediriger votre demande à la bonne personne.